- Which treatment modality should we choose for advanced hepatocellular carcinoma?
-
Kim DY
- KMID: 1117690
- Korean J Hepatol.
- 2010 Dec;16(4):353-354.
- doi: 10.3350/kjhep.2010.16.4.353
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer
-
Takekuma M, Kuji S, Tanaka A, Takahashi , Abe M, Hirashima
- KMID: 2160804
- J Gynecol Oncol.
- 2015 Jul;26(3):185-192.
- doi: 10.3802/jgo.2015.26.3.185
OBJECTIVE: The concept of platinum sensitivity and cross-resistance among platinum agents are widely known in the management of recurrent ovarian cancer. The aim of this study was to evaluate two... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase II Study of Combination Chemotherapy with Gemcitabine, 5-fluorouracil, and Cisplatin for Advanced Pancreatic Cancer
-
Choi SB, Lee HY, Yuh YJ, Kim SR
- KMID: 772776
- Korean J Gastroenterol.
- 2005 May;45(5):348-353.
BACKGROUND/AIMS: Gemcitabine has been the standard regimen for advanced pancreatic cancer, but the effect on the response rate and survival is still disappointing, leading to many trials of combination... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer
-
Lee KW, Kim JH, Yun T, Song EK, Na II, Shin H, Oh SY, Choi IS, Oh DY, Kim DW, Im SA, Kim TY, Lee JS, Heo DS, Bang YJ, Kim NK
- KMID: 1785799
- J Korean Med Sci.
- 2007 Sep;22(Suppl):S115-S121.
- doi: 10.3346/jkms.2007.22.S.S115
This study was performed to evaluate the efficacy and toxicity of low-dose paclitaxel/cisplatin chemotherapy in patients with metastatic or recurrent gastric cancer that had failed 5-fluorouracil/platinum-based chemotherapy. Thirty-two patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions
-
Maurer K, Michener C, Mahdi H, Rose PG
- KMID: 2413426
- J Gynecol Oncol.
- 2017 Jul;28(4):e38.
- doi: 10.3802/jgo.2017.28.e38
OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination chemotherapy of oral 5'-deoxy-5-fluorouridine and cisplatin in advanced gastric cancer: a phase II study
-
Ahn MJ, Han DS, Sohn JH, Jeon YC, Jun DW, Choi NW, Park HK, Baik HK, Lee HG, Nam YS, Choi IY
- KMID: 1038441
- J Korean Med Sci.
- 1998 Dec;13(6):612-616.
- doi: 10.3346/jkms.1998.13.6.612
This study was designed to test the activity and feasibility of 5'-deoxy-5-fluorouridine (5'-DFUR) and cisplatin combination therapy in the treatment of advanced gastric cancer. Nineteen patients with inoperable and/or ... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase II Study of Paclitaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
-
Hwang J, Cho SH, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, Lee JJ, Kim HJ, Chung IJ
- KMID: 1785814
- J Korean Med Sci.
- 2008 Aug;23(4):586-591.
- doi: 10.3346/jkms.2008.23.4.586
This phase II study evaluated the efficacy and safety of combination chemotherapy with paclitaxel, cisplatin, and 5-fluorouracil (5-FU) in advanced gastric cancer. Patients with histologically confirmed gastric adenocarcinoma were eligible... -
- CITED
-
- Close
- SHARE
-
- Close
- Concurrent Chemo-Radiation Therapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis
-
Kim JS, Han KH, Lee DY, Seong JS, Youn YH, Cheong JY, Ahn SH, Chon CY, Moon YM
- KMID: 863070
- Korean J Hepatol.
- 2002 Mar;8(1):71-79.
BACKGROUND/AIMS: Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis. This study was undertaken to evaluate the therapeutic effects of concurrent chemo-radiation therapy in advanced hepatocellular carcinoma... -
- CITED
-
- Close
- SHARE
-
- Close
- Orbital Metastatic Angiosarcoma
-
Hassane S, Fouad E, Said I, Karim R, Asmae N, Houcine C, Abdelbar O
- KMID: 1769091
- Korean J Ophthalmol.
- 2010 Dec;24(6):364-366.
- doi: 10.3341/kjo.2010.24.6.364
We report a case of a 48-year-old man who developed metastatic angiosarcoma in her left orbit. A 48-year-old man was first sent to us for a check up of proptosis... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Successful Intrapleural Chemotherapy with Cisplatin Plus Cytarabine for Intractable Malignant Pleural Effusion
-
Moon YW, Choi ST, Cho BC, Choi HJ, Kim YT
- KMID: 1786221
- Yonsei Med J.
- 2007 Dec;48(6):1035-1038.
- doi: 10.3349/ymj.2007.48.6.1035
When conventional treatments of malignant pleural effusion, such as repeated thoracentesis, closed thoracotomy and pleurodesis by instilled sclerosing agents, are ineffective, there are few alternative therapies available. Our case involves... -
- CITED
-
- Close
- SHARE
-
- Close
- Pulmonary Toxicity after a Quick Course of Combinatorial Vincristine, Bleomycin, and Cisplatin Neoadjuvant Chemotherapy in Cervical Cancer
-
Ki KD, Lee JM, Lee SK, Tong SY, Huh CY, Ryu JK, Kim KY
- KMID: 1779254
- J Korean Med Sci.
- 2010 Feb;25(2):240-244.
- doi: 10.3346/jkms.2010.25.2.240
Pulmonary toxicity is one of the most serious adverse effects associated with a quick course of vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy (NAC-VBP). The aim of this study was to... -
- CITED
-
- Close
- SHARE
-
- Close
- Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
-
Kim KH, Joo YD, Sohn CH, Shin HJ, Chung JS, Cho GJ, Shin SH, Kim YS, Lee WS
- KMID: 1785640
- Korean J Intern Med.
- 2009 Mar;24(1):37-42.
- doi: 10.3904/kjim.2009.24.1.37
BACKGROUND/AIMS: To date, an effective salvage chemotherapy regimen for the treatment of refractory or relapsing non-Hodgkin's lymphoma (NHL) has not been discovered. This study was conducted to evaluate the... -
- CITED
-
- Close
- SHARE
-
- Close
- ATP-Based Chemotherapy Response Assay in Primary or Recurrent Ovarian and Peritoneal Cancer
-
Lee M, Kim SW, Nam EJ, Cho H, Kim JH, Kim YT, Kim S
- KMID: 2070217
- Yonsei Med J.
- 2014 Nov;55(6):1664-1671.
- doi: 10.3349/ymj.2014.55.6.1664
PURPOSE: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status. MATERIALS AND METHODS: One... -
- CITED
-
- Close
- SHARE
-
- Close
- ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkins Lymphoma: A Single Center Experience
-
Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP, Huh J, Kim SB, Kim SW, Lee JL, Suh C
- KMID: 759841
- Korean J Intern Med.
- 2006 Sep;21(3):159-164.
- doi: 10.3904/kjim.2006.21.3.159
BACKGROUND: The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma... -
- CITED
-
- Close
- SHARE
-
- Close
- Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
-
Kim JH, Lee KW, Kim YH, Lee KH, Oh DY, Kim J, Yang SH, Im SA, Choi SH, Bang YJ
- KMID: 1713950
- J Korean Med Sci.
- 2010 May;25(5):684-690.
- doi: 10.3346/jkms.2010.25.5.684
The purpose of our study was to determine the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and to... -
- CITED
-
- Close
- SHARE
-
- Close
- A randomized trial comparing cisplatin plus 5-fluorouracil with or without levamisole in operable gastric cancer
-
Choi JS, Lee KH, Ahn MJ, Lee JS, Lee JH, Zang DY, Suh CW, Kim SW, Kim WG, Kim JC, Kim S, Park KC, Lee MS, Kim SH
- KMID: 1051578
- Korean J Intern Med.
- 1997 Jun;12(2):155-162.
OBJECTIVES: To determine the effectiveness and toxicity when levamisole was added to the adjuvant combination chemotherapy in patients with operable gastric cancer. METHODS: After en bloc resection of gastric cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
-
Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, Lee JJ, Na KJ, Kim HJ
- KMID: 1712743
- J Korean Med Sci.
- 2005 Aug;20(4):618-623.
- doi: 10.3346/jkms.2005.20.4.618
Although various combinations of chemotherapy regimens have been tried for patients with esophageal cancer, their duration of survival is extremely poor. In this study, we investigated the safety and clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results
-
Kim JS, Park YM, Kim NY, Yun HK, Lee KJ, Kim BH, Park SJ, Yeon JW, Jung G
- KMID: 1015571
- Korean J Hepatol.
- 2011 Jun;17(2):120-129.
- doi: 10.3350/kjhep.2011.17.2.120
BACKGROUND/AIMS: Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin (HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular carcinoma (HCC). However,... -
- CITED
-
- Close
- SHARE
-
- Close
- Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma
-
Wentrup R, Winkelmann N, Mitroshkin A, Prager M, Voderholzer W, Schachschal G, Jürgensen C, Büning C
- KMID: 2411976
- Gut Liver.
- 2016 May;10(3):470-475.
- doi: 10.5009/gnl15175
BACKGROUND/AIMS: Standard treatments are not available for hilar nonresectable cholangiocarcinoma (NCC). It is unknown whether combination therapy of photodynamic therapy (PDT) plus systemic chemotherapy is superior to PDT alone. METHODS: We... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion
-
Katanyoo K
- KMID: 2413205
- J Gynecol Oncol.
- 2017 Nov;28(6):e79.
- doi: 10.3802/jgo.2017.28.e79
OBJECTIVE: To evaluate treatment outcomes between stage IIIB cervical cancer with and without lower third of vaginal invasion (LTI) in terms of response to treatment and overall survival (OS). METHODS: Matching... -
- CITED
-
- Close
- SHARE
-
- Close
